omidenepag isopropyl

Omidenepag isopropyl is a small molecule prodrug used as an ophthalmic solution to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. After corneal penetration, it is hydrolyzed to its active metabolite, omidenepag, which acts as a selective agonist of the prostaglandin E2 (EP2) receptor. Activation of this receptor increases intracellular cAMP levels in the ciliary body and trabecular meshwork, promoting aqueous humor outflow through both trabecular and uveoscleral pathways. This mechanism provides an alternative for patients who do not respond adequately to FP receptor agonists like latanoprost. Omidenepag isopropyl was first approved in Japan in 2018 and received FDA approval in September 2022 for the reduction of elevated intraocular pressure[1][3][5][6].

Brand names

Omlonti

Other names

omidenepag isopropyl1187451-19-9